The type II fatty acid pathway (FAS-II) is a validated target for antimicrobial drug discovery. An activity-guided isolation procedure based on
Plasmodium falciparum enoyl-ACP reductase (
PfFabI) enzyme inhibition assay on the
n-hexane-, the
CHCl3- and the aq MeOH extracts of the Turkish marine sponge
Agelas oroides yielded six pure metabolites [24-ethyl-cholest-5α-7-en-3-β-ol (
1), 4,5-dibromopyrrole-2-carboxylic acid methyl ester (
2), 4,5-dibromopyrrole-2-carboxylic acid (
3), (
E)-oroidin (
4), 3-amino-1-(2-aminoimidazoyl)-prop-1-ene (
5), taurine (
6)] and some minor, complex fatty acid mixtures (
FAMA–
FAMG).
FAMA, consisting of a 1:2 mixture of (5
Z,9
Z)-5,9-tricosadienoic (
7) and (5
Z,9
Z)-5,9-tetracosadienoic (
8) acids, and
FAMB composed of
8, (5
Z,9
Z)-5,9-pentacosadienoic (
9) and (5
Z,9
Z)-5,9-hexacosadienoic (
10) acids in ≈3:3:2 ratio were the most active
PfFabI inhibitory principles of the hexane extract (IC
50 values 0.35 μg/ml). (
E)-Oroidin isolated as free base (
4a) was identified as the active component of the CHCl
3 extract. Compound
4a was a more potent
PfFabI inhibitor (IC
50 0.30 μg/ml = 0.77 μM) than the (
E)-oroidin TFA salt (
4b), the active and ma
jor component of the aq MeOH extract (IC
50 5.0 μg/ml). Enzyme kinetic studies showed
4a to be an uncompetitive
PfFabI inhibitor (
Ki: 0.4 ± 0.2 and 0.8 ± 0.2 μM with respect to substrate and cofactor). In addition,
FAMA and
FAMD (mainly consisting of methyl-branched fatty acids) inhibited FabI of
Mycobacterium tuberculosis (
MtFabI, IC
50s 9.4 and 8.2 μg/ml, respectively) and
Escherichia coli (
EcFabI, IC
50s 0.5 and 0.07 μg/ml, respectively). The ma
jority of the compounds exhibited in vitro antiplasmodial, as well as trypanocidal and leishmanicidal activities without cytotoxicity towards mammalian cells. This study represents the first marine metabolites that inhibit FabI, a clinically relevant enzyme target from the FAS-II pathway of several pathogenic microorganisms.